RFA
CBAY

Reilly Financial Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Reilly Financial Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-49,300
Closed -$172K – 953
2020
Q2 		$172K Hold
49,300
– – 0.02% 181
2020
Q1 		$73K Buy
+49,300
New +$82.8K 0.01% 250

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Reilly Financial Advisors's CBAY Position: Q3 2020 in Review

Reilly Financial Advisors sold out of Cymabay Therapeutics (CBAY) in Q3 2020, closing a stake of 49,300 shares — an estimated $172K sold.

Reilly Financial Advisors first reported a position in CBAY in Q1 2020 and held it in 2 quarters. The position peaked at $172K in Q2 2020. 120 funds tracked by Wall St. Rank hold CBAY as of Q3 2020.

  • Reilly Financial Advisors reported no remaining Cymabay Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Reilly Financial Advisors sold 49,300 Cymabay Therapeutics shares in Q3 2020, an estimated $172K.
  • Reilly Financial Advisors first reported a position in Cymabay Therapeutics in Q1 2020 and held it in 2 quarters.
  • Reilly Financial Advisors's Cymabay Therapeutics position peaked at $172K in Q2 2020.
  • 120 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2020.

Based on Reilly Financial Advisors's 13F filing for Q3 2020, filed 6 Nov 2020.